Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
TL;DR
Lifordi Immunotherapeutics' LFD-200 offers a competitive edge by targeting immune cells directly, reducing systemic toxicity and broadening steroid use in autoimmune treatments.
LFD-200 utilizes an Anti-VISTA monoclonal antibody to deliver glucocorticoids directly to immune cells, ensuring rapid uptake and sustained efficacy without off-target toxicity.
LFD-200's targeted therapy promises a safer, more effective treatment for autoimmune diseases, improving patient quality of life and reducing systemic side effects.
Discover how Lifordi's LFD-200 revolutionizes autoimmune treatment by delivering drugs directly to immune cells, offering hope for diseases like arthritis and asthma.
Found this article helpful?
Share it with your network and spread the knowledge!
Lifordi Immunotherapeutics, Inc. has taken a significant step forward in the treatment of autoimmune and inflammatory diseases with the presentation of preclinical data on LFD-200 at the European Alliance of Associations for Rheumatology (EULAR) meeting. The data highlights LFD-200's ability to deliver a glucocorticoid payload directly to immune cells, achieving targeted efficacy without the systemic toxicity associated with traditional steroid treatments.
The studies demonstrated that LFD-200 rapidly delivers its payload to immune cells, avoiding prolonged serum exposure and limiting uptake by off-target tissues. This targeted approach results in sustained glucocorticoid exposure in immune tissues for more than seven days, a stark contrast to the rapid clearance seen with dexamethasone. Importantly, LFD-200 showed no evidence of systemic glucocorticoid toxicity after extended dosing, a common limitation of current treatments.
These findings are particularly significant as they suggest LFD-200 could offer a new therapeutic avenue for a range of autoimmune and inflammatory conditions, including rheumatology, gastroenterology, pulmonology, and dermatology. The ability to achieve efficacy without systemic toxicity addresses a major unmet need in the treatment of these diseases, potentially improving patient outcomes and quality of life.
With a Phase 1 clinical study on the horizon, the medical community is keenly watching Lifordi's progress. The successful development of LFD-200 could revolutionize the treatment landscape for autoimmune and inflammatory diseases, offering hope to millions of patients worldwide.
Curated from Reportable
